الفهرس 
A Pharmaceutical Study on Nanocarriers as a Tool for Ocular Drug Delivery
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
Fungal infections of the eye are commonly happening. Most cases appear in hot and humid areas characterized by low socioeconomic levels and poor hygiene. In addition, the eye is a small, complex organ with small volume of tear fluid available for ocular drug retention and absorption. The tear film turnover and blinking of the eyes reduce the effective fraction of the applied dose available for absorption.The remaining fraction of the dose then must permeate through the tight junctions of corneal epithelium to be absorbed and provide therapy. Moreover, fungal infections of the eye show delayed onset of symptoms, then they become more difficult to treat. Treatment options in these cases are usually invasive e.g. the use of penetrating keratoplasty or necessitate the use of high dose of systemic and topical antifungals, finally leading to noncompliance of the patients. Recently, Voriconazole (VCZ), emerged as a promising drug for the treatment of life-threatening mycoses. It{u2019}s currently available only in oral and intravenous dosage forms, causing many untoward effects. When needed for ocular use, the lyophilized drug-cyclodextrin complex for intravenous administration is reconstituted and applied frequently to the eye, with limited ocular bioavailability